Sequantrix Launches Operations
Sequantrix identifies and validates novel, antifibrotic targets by leveraging one of the world’s largest human single-cell, multi-modal datasets in the...
Year: 2023
Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer
Has served in interim role since January 2023HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO)...
Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates
Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming...
HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patientsMUNICH, Germany, June 20, 2023 (GLOBE NEWSWIRE)...
Grace Breeding Announces Brazil Field Test Results of its ProMagen™ (WDS Bio-Activator) in Soybean Plants Demonstrating Boosted Yields
- Using ProMagen™ in combination with standard chemicals or other biological solutions demonstrated more efficient disease control and boosted yields...
Appeal of Delisting Determination
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage...
PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corp. (NASDAQ: PDSB), a clinical-stage company developing a growing...
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor...
aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
Presentations highlight efzofitimod’s novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. SAN DIEGO, June 20,...
STERIS Expands Healthcare Products Offering with Acquisition of Surgical Instrumentation Assets from Becton, Dickinson and Company for $540 million
A natural extension for STERIS in the operating room and sterile processing departmentA primarily consumables product portfolioTransaction expected to close...
Predictive Oncology Appoints Dr. Bernard A. Harris, Jr. to its Newly Formed Business Advisory Board
EAGAN, Minn., June 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence...
LifeMD Appoints William J. Febbo to its Board of Directors
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today...
Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and a 523-gene NGS Panel for Standard Evaluation of Myeloid Cancers
SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed...
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a...
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3 Continuing...
ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases,...
Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease
–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of...
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE...
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12...
Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of...